Effects of Imatinib Mesylate on Renin–Angiotensin System (RAS) Activity During the Clinical Course of Chronic Myeloid Leukaemia

Author： Sayitoglu M   Haznedaroğlu IC   Hatirnaz O   Erbilgin Y   Aksu S   Koca E   Adiguzel C   Bayik M   Akalin I   Gülbas Z   Akay M   Unal A   Kaynar L   Ovali E   Yilmaz M   Yenerel M   Dagdas S   Ozet G   Ar C   Aydin Y   Soysal T   Durgun B   Ozcebe O   Tukun A   Ilhan O   Ozbek U  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.37, Iss.4, 2009-07, pp. : 1018-1028

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib mesylate in the treatment of chronic myeloid leukaemia

By Druker Brian J  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. : 963-971

Informa Healthcare

Access to resources Recommend Favorite

Imatinib mesylate normalised the bone marrow of patients with chronic myeloid leukaemia

By  

Inpharma, Vol. 1, Iss. 1327, 2002-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Imatinib mesylate-resistant cells were present in a man with chronic myeloid leukaemia (CML) before treatment with the drug

By  

Inpharma, Vol. 1, Iss. 1390, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

AstraZeneca's lung cancer agent gefitinib [`Iressa'] is being launched at a 25% discount to the chronic myeloid leukaemia agent imatinib mesylate

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 412, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

The Pulmonary Renin-Angiotensin System

By  

Current Pharmaceutical Design, Vol. 9, Iss. 9, 2003-04 ,pp. : 715-722

Bentham Science Publishers

Access to resources Recommend Favorite